Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Learn how value tilts steer retirement portfolio index funds toward undervalued opportunities, balancing risk while pursuing higher long-term gains.
25,656 articlesEli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
SpaceX kicked off trading with a sharp first-day rally. This guide analyzes historical IPO patterns to estimate where...
Tech stocks aren’t falling because of headlines about conflicts. The bigger driver is AI infrastructure capex and mac...
As Micron gears up for its June earnings, a fresh investing angle centers on the idea that prediction: micron stock w...
Biotech headlines move markets. ImmunityBio, boosted by Anktiva's 700% revenue surge, sparked a rally that may signal...
As JJSF prepares for its 2026 earnings call, investors will scrutinize margins, pricing power, and capital allocation...
A new NVIDIA-backed player has stepped into the high-growth AI photonics space, challenging traditional data-center b...
A broad market rally lifted major indexes on Feb. 24 as traders anticipated Nvidia’s earnings and awaited remarks fro...
In April, nebius group stock popped as investors weighed cloud and AI catalysts. This piece breaks down the drivers, ...
Micron just broke mold by turning AI-driven memory demand into a clear investment thesis. This guide explains why the...
Boyd Group stock since its IPO has posted a meaningful climb. This piece breaks down the factors behind the move, wha...
As AI accelerates, Nvidia has driven eye-popping gains. But with new competitors and a crowded AI ecosystem, is Nvidi...